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Past studies have shown that upregulation of the anti-
apoptotic Bcl-2 family protein Mcl-1 is a major adaptive
mechanism of melanoma cells to endoplasmic reticulum
(ER) stress, and has an important role in resistance of the
cells to apoptosis. In this study, we show that the increase
in transcription of Mcl-1 in melanoma cells triggered
by pharmacological ER stress inducers is mediated by
the transcription factor Ets-1. By incremental deletion
analysis of the Mcl-1 promoter, we identiﬁed a DNA
fragment containing an Ets-1 binding site that is
transcriptionally responsive to ER stress. Mutations in
the Ets-1 binding site or knockdown of Ets-1 inhibited the
increase in Mcl-1, indicating that Ets-1 has a critical role
in transcriptional upregulation of Mcl-1. Similar to Mcl-
1, Ets-1 was transcriptionally upregulated by ER stress.
This was mediated by the IRE1a/XBP-1 branch of the
unfolded protein response, as upregulation of Ets-1 was
inhibited in melanoma cell lines deﬁcient in IRE1a or
XBP-1 established by short hairpin RNA knockdown.
Activation of the PI3k/Akt pathway downstream of
XBP-1 was also involved, in that inhibition of the path-
way blocked upregulation of Ets-1. Inhibition of Ets-1
enhanced ER stress-induced apoptosis in melanoma cell
lines and in fresh melanoma isolates, recapitulating the
effect of inhibition of Mcl-1. These results reveal a key
mechanism by which Mcl-1 is transcriptionally upregu-
lated in melanoma cells by ER stress, and identify Ets-1 as
a potential target for inhibition to sensitize melanoma
cells to apoptosis.
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Introduction
Melanoma continues to increase in incidence in many
parts of the world, but there is currently no curative
treatment once the disease has spread beyond the
primary site. This is largely due to resistance of
melanoma cells to induction of apoptosis by available
chemotherapeutic drugs and biological reagents
(Soengas and Lowe, 2003; Hersey et al., 2006). The
anti-apoptotic Bcl-2 family protein Mcl-1 is of particular
importance in resistance of melanoma to treatment, in
that its expression increases with melanoma progression
and is associated with poorer prognosis (Cory and
Adams, 2002; Mhaidat et al., 2007; Wang et al., 2007;
Zhuang et al., 2007; Jiang et al., 2009a). As a protein
with a rapid turn-over rate, Mcl-1 expression is
frequently regulated by post-translational mechanisms
(Zhong et al., 2005; Warr and Shore, 2008; Schwickart
et al., 2010). Nevertheless, an increase in the Mcl-1
protein levels often correlates with an increase in its
mRNA levels, mostly due to enhanced transcription
(Iglesias-Serret et al., 2003; Warr and Shore, 2008).
Several transcription factors including HIF1a and Stat3
are known to regulate Mcl-1 expression in various
cell types (Epling-Burnette et al., 2001; Iglesias-Serret
et al., 2003; Piret et al., 2005; Isomoto et al., 2005; Wang
et al., 2003).
A number of cellular stress conditions, such as
nutrient deprivation and alterations in glycosylation
status, lead to accumulation of unfolded and/or
misfolded proteins in the endoplasmic reticulum (ER)
lumen and cause ER stress (Harding et al., 2002; Zhang
and Kaufman, 2004; Schroder and Kaufman, 2005). The
ER responds by activation of a range of signaling
pathways that are collectively termed the ER stress
response or the unfolded protein response (UPR)
(Harding et al., 2002; Zhang and Kaufman, 2004;
Schroder and Kaufman, 2005), which is fundamentally
a cyto-protective response, but excessive or prolonged
UPR can lead to apoptotic cell death. However, we have
found that melanoma cells have largely adapted to ER
stress and are resistant to ER stress-induced apoptosis
(Hersey and Zhang, 2008; Jiang et al., 2008). In
addition, we have shown that upregulation of Mcl-1 is
a major adaptive mechanism (Hersey and Zhang, 2008;
Jiang et al., 2008). Although transcriptional regulation
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tion of Mcl-1 (Jiang et al., 2008), the precise mechan-
ism(s) responsible remains to be deﬁned.
E26 transformation-speciﬁc sequence (Ets)-1 is a
member of the Ets family of transcription factors that
have roles in many biologic processes such as cell
growth and survival (Dittmer, 2003; Hahne et al., 2008).
Increased Ets-1 expression has been reported to
correlate with grade of malignancy and poorer prog-
nosis in a number of cancers (Davidson et al., 2001;
Span et al., 2002). In melanoma, high levels of Ets-1 are
often associated with progression of the disease (Poser
and Bosserhoff, 2004; Rothhammer et al., 2004;
Torlakovic et al., 2004). The role of Ets-1 in regulation
of apoptosis seems to be cell type-dependent, as it
protects against apoptosis in some cell types, but induces
apoptosis in others (Bories et al., 1995; Sato et al., 2001;
Teruyama et al., 2001; Dittmer, 2003). Although the
mechanisms involved remain to be better understood, it
is known that Ets-1 can regulate the expression of
the BH3-only protein Bid in endothelial cells and the
expression of Bcl-2 in colon cancer cells (Li et al., 2000;
Sato et al., 2001).
We have examined the mechanism responsible for
the increase in Mcl-1 at the transcriptional level in
melanoma cells upon pharmacological induction of ER
stress. We show in this report that transcriptional
upregulation of Mcl-1 by ER stress is mediated by
Ets-1 that is also upregulated by the IRE1a/XBP-1
branch of the UPR. Moreover, we demonstrate that
activation of the PI3k/Akt pathway mediated by XBP-1
is involved in upregulation of Ets-1, and that inhibition
of Ets-1 recapitulates, at least in part, the effect of
inhibition of Mcl-1 on sensitivity of melanoma cells to
ER stress-induced apoptosis.
Results
The region between  205 and  175 of the Mcl-1
promoter is essential for transcriptional upregulation
of Mcl-1 in melanoma cells under ER stress
Past studies have shown that a transcriptional increase is
involved in upregulation of Mcl-1 in melanoma cells
upon ER stress (Jiang et al., 2008). To determine the
active region of the Mcl-1 promoter responsible for this,
a luciferase reporter containing sequences between
 1300 and þ10 (pGL3-Mcl-1 1300/þ10) (numbers
relative to the transcription start site) was constructed
and transiently transfected into Mel-CV and MM200
cells (Figure 1a). This region encompasses a number of
predicted binding sites for various transcription factors
including NF-kB, Stat3, Ets, CREBP and Sp1 (Akgul
et al., 2000). Treatment with Tunicamycin (TM) that
induces ER stress by inhibition of glycosylation, resulted
in signiﬁcant increases in transcriptional activity of the
reporter in both cell lines (Po0.05, two-tailed Student’s
t-test) (Figure 1b) (Elbein, 1987). In contrast, exposure
to TM did not cause any increase in the transcriptional
activity of the luciferase reporter containing the  2600/
 1200 upstream region of the Mcl-1 promoter (Supple-
mentary Figure S1). Induction of ER stress by TM
was corroborated by the increased levels of GRP78, an
indicator of activation of the UPR (Supplementary
Figure S2) (Jiang et al., 2008).
To further map the site within the  1300/þ10 region
responsible for the TM-induced increase in Mcl-1
transcription, a series of incremental deletion reporter
constructs contained in this region were analyzed
(Figure 1a). As shown in Figure 1b, TM increased
transcriptional activity in all the constructs except
for pGL3-Mcl 175/þ10 and pGL3-Mcl-1-65/þ10.
Figure 1 The  205/ 175 region of the Mcl-1 promoter is essential for transcriptional upregulation of Mcl-1 in melanoma cells under
ER stress. (a) A schematic illustration of construction of the luciferase reporter constructs. (b) Mel-CV (left) and MM200 (right) cells
were transiently transfected with indicated pGL3-basic based reporter constructs. After 24h, cells were treated with TM (3mM) for a
further 16h followed by measurement of the luciferase activity. Bars, s.e. (n¼3).
Ets-1 regulates Mcl-1 in melanoma
L Dong et al
3717
OncogeneThe shortest fragment that was transcriptionally
responsive to TM was pGL3-Mcl-1 205/þ10. There-
fore, the region between  205 and  175 is required for
transcriptional upregulation of Mcl-1 in melanoma cells
by ER stress. This was conﬁrmed in experiments
with another ER stress inducer thapsigargin (TG)
(Supplementary Figure S3) (Sagara and Inesi, 1991).
An Ets binding region located between  205 and  175
of the Mcl-1 promoter is transcriptionally responsive
to ER stress
The  205/ 175 fragment of the Mcl-1 promoter
contains a consensus binding region of the transcription
factor c-Rel (Figure 2a) (Akgul et al., 2000), which is
known to participate in regulation of cell survival (Chen
et al., 2000). We therefore tested if this region has a role
in activation of the Mcl-1 promoter by ER stress.
Mutation of the region abolished the transcriptional
activity of the luciferase reporter after treatment
with TM (Figures 2a and b). However, there was no
association between c-Rel and the segment spanning
from  205 to þ10 of the Mcl-1 promoter as shown
in chromatin immunoprecipitation (ChIP) assays
(Figure 2c), suggesting that transcriptional activation
of the  205/ 175 fragment by ER stress is not mediated
by c-Rel.
Intriguingly, within the c-Rel consensus motif is also a
predicted binding site for Ets transcription factors
(Akgul et al., 2000). We therefore examined if Ets-1
and -2 are involved in activation of the region. ChIP
assays demonstrated that Ets-1, but not Ets-2, bound
to the  205/þ10 segment, which was enhanced by
treatment with TM (Figure 2c). Binding of Ets-1 to the
region was also conﬁrmed in electrophoretic mobility
shift assay (EMSA) (Figure 2d). The nuclear protein
complexed with the labeled probe (the segment from
 205 to  175) was diminished with the addition of an
antibody against Ets-1, but not an antibody against
c-Rel or Ets-2. A supershift in the presence of an
anti-Ets1 antibody was not observed in the EMSA
assay, presumably due to steric interference between the
antibody and oligonucleotide binding, which prevented
formation of the antibody–DNA–protein super-com-
plex, as reported previously (Myers et al., 2005; Zhang
et al., 2010). Nevertheless, these results suggest that
binding of Ets-1 to the  205/ 175 region may
be responsible for activation of the Mcl-1 promoter in
melanoma cells under ER stress.
Ets-1 is responsible for transcriptional upregulation
of Mcl-1 in melanoma cells upon ER stress
As shown in Figure 3a, TM induced a rapid increase in
Ets-1 along with Mcl-1 at the protein level. Similarly,
Figure 2 An Ets binding region between  205 and  175 of the Mcl-1 promoter is transcriptionally responsive to ER stress.
(a) A schematic illustration of a potential c-Rel and Ets-1 binding motif located within the  250/ 175 region of the Mcl-1 promoter.
The Ets consensus binding motif is boxed in highlighted in gray. Experimental mutagenesis of the region is also depicted. (b) Mel-CV
and MM200 cells were transiently transfected with the pGL3-basic-based reporter constructs, pGL3-vector, pGL3-Mcl-1 205/þ10
(pGL3-Mcl-1), and a reporter with the c-Rel binding region mutated as shown in (a) (pGL3-Mcl-1-mut), respectively. After 24h, cells
were treated with TM (3mM) for a further 16h followed by measurement of the luciferase activity. (c) Formaldehyde-cross-linked
chromatin of Mel-CV and MM200 cells with or without treatment with TM (3mM) for 16h were subjected to immunoprecipitation
with antibodies against Ets-1, Ets-2 and c-Rel, respectively. The precipitates were subjected to PCR ampliﬁcation using primers for the
 205/þ10 region of the Mcl-1 promoter. (d) Nuclear extracts of MM200 cells with treatment with TM (3mM) for 16h were subjected
to super shift assay. Comp: competitor; NE, nuclear extracts; SC, speciﬁc competitor. E, the complex formed in the presence of nuclear
extracts with labeled oligonucleaotides. Bars, s.e. (n¼3).
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be inhibited by pretreatment with actinomycin D
(Figure 3b), indicating that this was due to a transcrip-
tional increase, rather than a change in the mRNA
stability. To conﬁrm transcriptional activation of Ets-1
by TM in melanoma cells, a luciferase reporter contain-
ing a 2.5kb fragment of the Ets-1 promoter was
constructed and transiently transfected into Mel-CV
and MM200 cells, as described previously (Jorcyk et al.,
1997; Wagner et al., 2008). As shown in Figure 3c,
treatment with TM induced signiﬁcant increases in
transcriptional activity of the reporter in both cell lines
(Po0.05, two-tailed Student’s t-test). Upregulation
of Ets-1 by ER stress was conﬁrmed in Mel-CV and
MM200 cells treated with TG (Figure 3d), and in
another four melanoma cell lines treated with TM
(Supplementary Figure S4). Notably, treatment with
TM did not cause any increase in a melanocyte line
(Supplementary Figure S4).
We next tested if inhibition of Ets-1 expression blocks
ER stress-induced upregulation of Mcl-1. Knockdown
of Ets-1 by Small RNA interference (siRNA) inhibited
the transcriptional response of the luciferase reporter
containing the Ets-1 binding site (pGL3-Mcl-1 205/
þ10) even in the presence of TM (Po0.05, two-tailed
Student’s t-test) (Figures 4a, b and Supplementary
Figure S5). Consistently, Ets-1 siRNA signiﬁcantly
inhibited upregulation of the endogenous Mcl-1 mRNA
by TM in both cell lines (Po0.05, two-tailed Student’s
t-test) (Figure 4b).
To further conﬁrm the role of Ets-1 in transcriptional
upregulation of Mcl-1, we transfected complimentary
DNA encoding Ets-1 with or without co-transfection
of the luciferase reporters pGL3-Mcl-1 205/þ10 into
MM200 and Mel-CV cells (Figures 4c and d). Over-
expression of Ets-1 markedly enhanced the transcrip-
tional activity of the reporters (Po0.05, two-tailed
Student’s t-test), and as anticipated, also increased the
endogenous Mcl-1 mRNA expression in both cell lines
(Figure 4d).
Upregulation of Ets-1 by ER stress is mediated by XBP-1
To examine the signaling pathways of the UPR
responsible for upregulation of Ets-1 in melanoma cells
under ER stress, we established melanoma cell lines
Figure 3 ER stress transcriptionally upregulates Ets-1 in melanoma cells. (a) Whole cell lysates from Mel-CV and MM200 cells with
or without treatment with TM (3mM) for indicated periods were subjected to western blot analysis. (b) Mel-CV and MM200 cells with
or without pretreatment with actinomycin D (3mg/ml) for 1h were treated with TM (3mM) for 16h. Total RNA was subjected to qPCR
analysis for Ets-1 mRNA expression. The relative abundance of mRNA expression before treatment was arbitrarily designated as 1.
(c) A luciferase reporter containing a 2.5kb fragment of the Ets-1 promoter was constructed and transiently transfected into Mel-CV
and MM200 cells. After 24h, cells were treated with TM (3mM) for a further 16h followed by measurement of the luciferase activity.
(d) Mel-CV and MM200 cells were treated with TG (1mM) 16h. Left panel: total RNA was subjected to qPCR analysis for Ets-1
mRNA expression. The relative abundance of mRNA expression in parental cells was arbitrarily designated as 1. Right: whole cell
lysates were subjected to western blot analysis. Bars, s.e. (n¼3).
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of the UPR, IRE1a, ATF6 and PERK, with short
hairpin RNA (shRNA) knockdown. Figure 5a
shows that deﬁciency in IRE1a or ATF6, but not
deﬁciency in PERK, partially inhibited upregulation of
Ets-1 by TM. Consistently, IRE1a or ATF6 deﬁciency
recapitulated partially the effect of siRNA knockdown
of Ets-1 on the expression of Mcl-1 at the mRNA
level (Figure 5b).
The IRE1a and ATF6 pathways of the UPR converge
on XBP-1 (Harding et al., 2002; Zhang and Kaufman,
2004; Schroder and Kaufman, 2005). We therefore
examined if XBP-1 has a role in ER stress-induced
upregulation of Ets-1 in Mel-CV and MM200 cells, with
XBP-1 stably knocked down by shRNA. Figure 5c
shows that deﬁciency in XBP-1 inhibited upregulation of
Ets-1 by TM, indicative of a critical role of XBP-1 in
upregulation of Ets-1 in melanoma cells under ER
stress. Similar to IRE1a or ATF6 deﬁciency, inhibition
of XBP-1 by shRNA recapitulated, in part, the effect of
inhibition of Ets-1 by siRNA on the expression of Mcl-1
mRNA (Supplementary Figure S6).
We examined if XBP-1 as a transcription factor is
directly responsible for transcriptional upregulation
Figure 4 Ets-1 is responsible for transcriptional upregulation of Mcl-1 by ER stress in melanoma cells. (a) Mel-CV and MM200 cells
were transfected with the control and Ets-1 small RNA interference (siRNA), respectively. Left panel: After 24h, cells were treated
with TM (3mM) for a further 16h. Total RNA was subjected to qPCR analysis for Ets-1 mRNA expression. The relative abundance of
mRNA expression in parental cells was arbitrarily designated as 1. Right panel: After 24h, whole cell lysates were subjected to western
blot analysis. Quantitation of the bands showed that the Ets-1 siRNA inhibited Ets-1 expression by 78 and 82% in Mel-CV and
MM200 cells, respectively. (b) Upper panel: Mel-CV cells were co-transfected with the control and Ets-1 siRNA and the pGL3-basic-
based luciferase reporter constructs, pGL3-vector and pGL3-Mcl-1 205/þ10 of the Mcl-1 promoter, respectively. After 24h, cells
were treated with the vehicle control (control) or TM (3mM) for a further 16h, followed by measurement of the luciferase activity.
Lower panel: Mel-CV and MM200 cells were transfected with the control and Ets-1 siRNA. After 24h, cells were treated with TM
(3mM) for a further 16h. Total RNA was subjected to qPCR analysis for Mcl-1 mRNA expression. The relative abundance of mRNA
expression in cells transfected with the control siRNA without treatment with TM was arbitrarily designated as 1. (c) Mel-CV and
MM200 cells were transiently transfected with the vector alone or complimentary DNA encoding Ets-1. After 24h, whole cell lysates
were subjected to western blot analysis. (d) Upper panel: Mel-CV and MM200 cells co-transfected with complimentary DNA encoding
Ets-1 and the pGL3-basic-based luciferase reporter constructs, pGL3-vector and pGL3-Mcl-1 205/þ10 of the Mcl-1 promoter,
respectively. After 24h, the luciferase activity was measured. Lower panel: Mel-CV and MM200 cells were transiently transfected
with the vector alone or complimentary DNA encoding Ets-1. After 24h, total RNA was subjected to qPCR analysis for
Mcl-1 mRNA expression. The relative abundance of mRNA expression in cells with mock transfection was arbitrarily designated as 1.
Bars, s.e. (n¼3).
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(Harding et al., 2002; Zhang and Kaufman, 2004;
Schroder and Kaufman, 2005). Although examination
of the ﬂanking genomic DNA region identiﬁed a
potential XBP-1 binding site located 1775–1793bp
upstream of the Ets-1 transcription start site (data not
shown), there was no binding of XBP-1 to the Ets-1
promoter as shown in both EMSA and ChIP assays
(data not shown).
We have previously found that XBP-1 mediates ER
stress-induced activation of Akt in melanoma cells,
which is known to have a role in regulation of Mcl-1
transcription (Jiang et al., 2009b). We therefore tested
the relationship between the activation of Akt and
upregulation of Ets-1. As shown in Figure 5d, treatment
with the PI3k inhibitor LY294002 blocked activation of
Akt and inhibited upregulation of Ets-1 induced by TM.
Notably, knockdown of Akt3, the major isoform of Akt
in melanoma (Jiang et al., 2009b), reduced the basal
levels of Ets-1, suggesting that the PI3k/Akt pathway
may have a role in regulating constitutive expression
of Ets-1 in melanoma cells (Figure 5e). Although the
addition of TM caused a threefold increase in Ets-1 in
cells transfected with the control siRNA, there was only
a 1.4-fold increase in cells with Akt3 knocked down
(Figure 5e), indicating that activation of Akt down-
stream of XBP-1 is involved in ER stress-induced
upregulation of Ets-1.
Figure 5 XBP-1 mediates upregulation of Ets-1 in melanoma cells under ER stress. (a) Mel-CV and MM200 cells were transfected
with the control, IRE1a, ATF6 and PERK shRNA, respectively. Upper panel: whole cell lysates were subjected to western blot
analysis. Quantitation of the bands showed that the IRE1a, ATF6 and PERK shRNA inhibited IRE1a, ATF6 and PERK expression
by 71 and 70%, 67 and 75%, 76 and 78%, in Mel-CV and MM200 cells, respectively. Lower panel: whole cell lysates from cells treated
with or without TM (3mM) for 16h were subjected to western blot analysis. (b) Mel-CV and MM200 cells with or without IRE1a and
ATF6 knocked down by shRNA, respectively, were treated with TM (3mM) for 16h. Total RNA was subjected to qPCR analysis for
Mcl-1 mRNA expression. The relative abundance of mRNA expression in cells carrying the control shRNA without treatment with
TM was arbitrarily designated as 1. (c) Mel-CV and MM200 cells were transfected with the control and XBP-1 shRNA, respectively.
Upper panel: whole cell lysates were subjected to western blot analysis. Quantitation of the bands showed that the XBP-1 shRNA
inhibited XBP-1 expression by 82 and 85% in Mel-CV and MM200 cells, respectively. Lower panel: whole cell lysates from cells treated
with or without TM (3mM) for 16h were subjected to western blot analysis. (d) Mel-CV and MM200 cells with or without pretreatment
with the PI3k inhibitor LY294002 (20mM) for 1h were treated with TM (3mM) for a further 16h. Whole cell lysates were subjected to
western blot analysis. (e) MM200 cells were transfected with the control or Akt3 small RNA interference (siRNA). Upper panel: After
24h, whole cell lysates were subjected to western blot analysis. Quantitation of the bands showed that the Akt3 siRNA inhibited Akt3
expression by 90%. Lower panel: After 24h, cells were treated with TM (3mM) for a further 16h. Whole cell lysates were subjected to
western blot analysis. The intensity of the Ets-1 bands was quantitated and the value in cells transfected with the control siRNA
without treatment with TM was arbitrarily designated as 1. The relative expression level of Ets-1 in each sample was depicted below the
corresponding blot.
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apoptosis
Because Mcl-1 has a critical role in protection of
melanoma cells from ER stress-induced apoptosis
(Hersey and Zhang, 2008; Jiang et al., 2008), we
examined whether Ets-1 has a similar role. As expected,
inhibition of Ets-1 by siRNA rendered Mel-CV and
MM200 cells sensitive to apoptosis induced by TM
(Figure 6a), which was conﬁrmed by induction of
caspase-3 activation (Figure 6b). This sensitization
could be blocked by overexpression of Mcl-1, and was
not further enhanced in melanoma cells deﬁcient in
Mcl-1 (Figures 6c, d and Supplementary Figure S7),
suggesting that it was mediated by downregulation of
Mcl-1. Similarly, inhibition of Ets-1 also sensitized
Mel-CV and MM200 cells to apoptosis induced by TG
(Supplementary Figure S8).
We next examined the effect of inhibition of Ets-1 on
responses to ER stress in fresh melanoma isolates, which
may more closely reﬂect the in vivo situation where the
cells are resistant to ER-stress-induced apoptosis
(Nguyen et al., 2001; Jiang et al., 2007). Freshly isolated
melanoma cells expressed in general relatively high levels
of Ets-1 in comparison with cultured melanocytes
(Supplementary Figure S9A). As reported before
(Liu et al., 2009; Jiang et al., 2009b), neither TM nor
TG induced signiﬁcant apoptosis in fresh melanoma
isolates (o20% apoptotic cells) (Figure 6e). However,
when Ets-1 was knocked down, there were signiﬁcant
increases in induction of apoptosis by the compounds
(Po0.05, respectively, two-tailed Student’s t-test)
(Figure 6e and Supplementary Figure S9B).
Discussion
The above results extend our previous ﬁnding that
Mcl-1 is upregulated in melanoma cells under ER stress,
by showing that Ets-1 is responsible for the transcrip-
tional increase in Mcl-1 (Jiang et al., 2008). They show
that Ets-1 is also upregulated downstream of the IRE1a/
XBP-1 branch of the UPR, and that this is associated
with activation of the PI3k/Akt pathway. Moreover,
the results demonstrate a role of Ets-1 in protection of
melanoma cells against ER stress-induced apoptosis,
which recapitulates, at least in part, the effect
of inhibition of Mcl-1 on sensitivity of melanoma cells
to apoptosis induced by ER stress.
Mcl-1 is of particular importance in melanoma, as its
expression increases with melanoma progression, is
associated with poorer prognosis, and is a key adaptive
mechanism of melanoma cells to cellular stress condi-
tions including ER stress (Wang et al., 2007; Zhuang
et al., 2007, 2009, 2010). Although Mcl-1 is regulated by
a number of signaling pathways (Epling-Burnette et al.,
2001; Harding et al., 2002; Iglesias-Serret et al., 2003;
Wang et al., 2003; Isomoto et al., 2005; Piret et al., 2005;
Warr and Shore, 2008), upregulation of Mcl-1 by the
UPR appears to be characteristic of melanoma cells, in
that Mcl-1 is commonly downregulated by ER stress in
other cell types (Fritsch et al., 2007). Our previous
results have shown that upregulation of Mcl-1 in
melanoma cells upon ER stress involves a transcrip-
tional increase (Jiang et al., 2008). In the present study,
we identiﬁed Ets-1 as a key transcription factor that
activates Mcl-1 transcription during ER stress in
melanoma cells. This was demonstrated by (1) the
shortest fragment of the Mcl-1 promoter responsive to
ER stress contained a consensus binding site of Ets;
(2) Ets-1 bound directly to this site, which was enhanced
by induction of ER stress; (3) mutations in this site
diminished ER stress-induced activation of the Mcl-1
promoter; and (4), knockdown of Ets-1 inhibited
activation of Mcl-1 transcription induced by ER stress,
whereas overexpression of Ets-1 enhanced Mcl-1 pro-
moter activity leading to increased Mcl-1 expression.
Even though we cannot exclude involvement of changes
in the Mcl-1 protein turnover rate, these results clearly
demonstrate an important role of Ets-1-mediated
increases in Mcl-1 at the transcriptional level in its
upregulation induced by ER stress in melanoma cells.
Ets-1 is expressed at high levels in many types of
cancers, and is involved in many biological processes in
cancer cells such as cell growth and survival (Davidson
et al., 2001; Span et al., 2002; Dittmer, 2003; Hahne
et al., 2008). In melanoma, the levels Ets-1 were similarly
found to be higher than those in benign melanocytic
lesions and melanocytes, and to increase with progres-
sion of the disease (Poser and Bosserhoff, 2004;
Rothhammer et al., 2004; Torlakovic et al., 2004).
Consistently, the results in this study also showed that
Ets-1 was commonly expressed at high levels in fresh
melanoma isolates. Although the role of Ets-1 in
regulation of apoptosis may vary between different cell
types (Bories et al., 1995; Teruyama et al., 2001), our
ﬁnding that Ets-1 was responsible for transcriptional
upregulation of Mcl-1 in melanoma cells subjected
to ER stress indicates that it is critical in protection of
melanoma cells against ER stress-induced apoptosis.
It is conceivable that, like Mcl-1, Ets-1 may also
contribute to resistance of melanoma cells to apoptosis
induced by agents other than those that induce ER stress
(Liu et al., 2009; Jiang et al., 2009c).
An important ﬁnding of this study is upregulation of
Ets-1 by ER stress in melanoma cells. This appeared
to be due to a transcriptional mechanism. Upregulation
of Ets-1 by ER stress was partially inhibited in
melanoma cells deﬁcient in IRE1a or ATF6, indicating
that these branches of the UPR are involved in the ER
stress-triggered increase in Ets-1 in melanoma cells. On
activation, the RNase activity of IRE1a cleaves XBP1
mRNA, generating a splicing variant that encodes a
potent transcription factor (Harding et al., 2002; Zhang
and Kaufman, 2004; Schroder and Kaufman, 2005).
As a transcription factor, activated ATF6 activates
transcription of UPR target genes including XBP-1
(Harding et al., 2002; Zhang and Kaufman, 2004;
Schroder and Kaufman, 2005). The convergence of the
IRE1a and ATF6 pathways on XBP-1 suggests that
XBP-1 may be involved in upregulation of Ets-1 by the
UPR. This was validated in melanoma cells with XBP-1
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with the essential role of XBP-1 in upregulation of
Mcl-1, as reported previously (Jiang et al., 2008).
Consistent with our previous ﬁnding that activation
of the PI3k/Akt pathway by XBP-1 is involved in
upregulation of Mcl-1 by the UPR in melanoma cells
(Jiang et al., 2009b), we found in this study that
activation of PI3k/Akt downstream of XBP-1 had a
role in ER stress-induced upregulation of Ets-1. The
mechanism(s) by which the PI3K/Akt pathway mediates
regulation of Ets-1 remains to be determined, but it is
known that activation of Akt increases the expression of
Figure 6 Inhibition of Ets-1 renders cultured melanoma cells and fresh melanoma isolates sensitive to ER stress-induced apoptosis.
(a) Mel-CV and MM200 cells were transfected with the control and Ets-1 small RNA interference (siRNA), respectively. Left panel:
After 24h, cells were treated with TM (3mM) for a further 16h. Total RNA was subjected to qPCR analysis for Ets-1 mRNA
expression. The relative abundance of mRNA expression in parental cells was arbitrarily designated as 1. Right panel: After 24h, cells
were treated with TM (3mM) for a further 48h. Apoptotic cells were quantitated by the propidium iodide method. (b) Mel-CV and
MM200 cells were transfected with the control and Ets-1 siRNA, respectively. After 24h, cells were treated with TM (3mM) for a
further 36h. Whole cell lysates were then subjected to western blot analysis. The arrow heads point to a non-speciﬁc band generated by
the antibody against caspase-3. (c) Upper panel: whole cell lysates from MM200 cells stably transfected with the vector alone or
complimentary DNA encoding Mcl-1 were subjected to western blot analysis. Lower panel: MM200 cells stably transfected with
complimentary DNA encoding Mcl-1 were transfected with the control or Ets-1 siRNA. After 24h, whole cell lysates were subjected to
western blot analysis. Quantitation of the bands showed that the Ets-1 siRNA inhibited Ets-1 expression by 80%. (d) MM200 cells
stably transfected with complimentary DNA encoding Mcl-1 were transfected with the control or Ets-1 siRNA. After 24h, cells were
treated with TM (3mM) for a further 48h. Apoptotic cells were quantitated by the propidium iodide method. (e) Upper panel: Mel-KD
and Mel-BE fresh melanoma isolates were transfected with the control or Ets-1 siRNA. After 24h, whole cell lysates were subjected to
western blot analysis. Quantitation of the bands showed that the Ets-1 siRNA inhibited Ets-1 expression by 82 and 78% in Mel-KD
and Mel-BE cells, respectively. Lower panel: Mel-KD and Mel-BE cells were transfected with the control or Ets-1 siRNA. After 24h,
cells were treated with TM (3mM) for a further 48h. Apoptotic cells were quantitated by the propidium iodide method. Bars, s.e.
(n¼3).
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Oncogenethe transcription factors AP1 and AP2 that regulate Ets-
1 transcription (Majeacuterus et al., 1992; Dittmer,
2003). Some other transcription factors that have been
shown to transcriptionally upregulate Ets-1 include Sp1,
HIF-1 and Ets-1 itself (Majeacuterus et al., 1992;
Dittmer, 2003; Hahne et al., 2008).
Our ﬁnding that Ets-1 has a role in protection
of freshly isolated melanoma cells against ER stress-
induced apoptosis is signiﬁcant, as they may reﬂect more
closely responses of melanoma cells to ER stress in vivo
(Nguyen et al., 2001; Jiang et al., 2007). The relatively
high levels of Ets-1 expression is conceivably a
consequence of activation of the UPR (Zhuang et al.,
2009; Jiang et al., 2009c), and a means of adaptation to
chronic ER stress conditions encountered by melanoma
cells in vivo. Collectively, results in this study reveal a
key mechanism responsible for transcriptional upregula-
tion of Mcl-1 by ER stress in melanoma cells, and
identify upregulation of Ets-1 as part of the adaptive
mechanism of the cells to ER stress. Ets-1 may therefore
be a potential target for the treatment of melanoma
in combination with therapeutics that induce ER stress.
Materials and methods
Cell culture and reagents
Human melanoma cell lines Me4405, ME1007, Mel-CV,
Sk-Mel-28, Sk-Mel-110 and MM200 have been described
previously and were cultured in Dulbecco’s modiﬁed Eagle’s
medium containing 5% fetal calf serum (Commonwealth
Serum Laboratories, Melbourne, VIC, Australia) (Gillespie
et al., 2005). DNA for cell line authentication was extracted
from all the cell lines while cultured for this study. Individual
cell line authentication was conﬁrmed using the AmpFlSTR
Identiﬁler PCR Ampliﬁcation Kit from Applied Biosystems
(Mulgrave, VIC, Australia) and GeneMarker V1.91 software
(SoftGenetics LLC, State College, PA, USA). A panel of 16
markers was tested, and each cell line had a distinct indivi-
dual set of markers present. TM and TG were purchased
from Sigma-Aldrich (Castle Hill, NSW, Australia). The PI3K
inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
(LY294002), was purchased from Calbiochem (Kilsyth, VIC,
Australia). The mouse monoclonal antibodies against Mcl-1
and the rabbit polyclonal antibodies (Abs) against Ets-1,
Ets-2, c-Rel, XBP-1, GRP78, IRE1a, ATF6 and PERK were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The rabbit antibodies against Akt, phospho-Akt (Ser473)
were from Cell Signaling Technology (Danvers, MA, USA). The
rabbit polyclonal antibodies against caspase-3 were from
Stressgen Biotechnologies (Victoria, BC, Canada).
Fresh melanoma isolates
Isolation of melanoma cells from fresh surgical specimens was
carried out as described previously (Jiang et al., 2010).
Apoptosis
Quantitation of apoptotic cells was carried out using
propidium iodide as described elsewhere (Jiang et al., 2010;
Yang et al., 2010).
Western blot analysis
Western blot analysis was carried out as described previously
(Jiang et al., 2010; Yang et al., 2010). The intensity of bands
was quantitated relative to corresponding GAPDH bands with
the Bio-Rad VersaDoc image system (Bio-Rad, Regents Park,
NSW, Australia).
Quantitative reverse transcription and real-time–PCR
Quantitative reverse transcription and real-time PCR was
performed as described previously (Jiang et al., 2010; Yang
et al., 2010). The primers used for PCR are as follows: ETS1:
sense, 50-GTCGTGGTAAACTCGG-30, anti-sense, 50-CAGC
AGGAATGACAGG-30; Mcl-1: sense, 50-CTTACGACGGG
TTGGG-30, anti-sense, 50-GGTTCGATGCAGCTTTCTTG
G-30; c-Rel: sense, 50-TTGGACAAGAACGCAGAC-30, anti-
sense, 50-CAGGAGGAAGAGCAGTCGT-30.
siRNA
The siRNA constructs used were obtained as the siGENOME
SMARTpool reagents (Dharmacon, Lafayette, CO, USA),
c-Rel siGENOME SMARTpool (M-004768-01-0010), Ets-1
siGENOME SMARTpool (M-003887-00-0010), AKT3 si-
GENOME SMARTpool (M-003002-02-0010), and siGENO
ME Non-targeting SiRNA pool (D-001206-13-20). Transfec-
tion of siRNA pools was carried out as described previously
(Jiang et al., 2010; Yang et al., 2010).
shRNA
Sigma MISSION Lentiviral Transduction Particles for
shRNA-mediated knockdown of Mcl-1 were purchased from
Sigma-Aldrich and used as described previously (Castle Hill,
NSW, Australia) (Jiang et al., 2008).
Luciferase-reporter constructs
The Mcl-1 promoter sequence from 1300bp upstream to 10bp
downstream of the human Mcl-1 gene transcription start site
was cloned by genomic PCR using human genomic DNA as a
template. Deletions of the promoter were generated by PCR
with 50 primers and a ﬁxed 30 primer. The sequences of these
forward primers were: 50-GCTAGCAACTGATCAATGTAC
TTTGTAATCT-30(-1300/10), 50-GCTAGCATTTGGTAAA
AAACCTCTGGCG-30(-300/10), 50-GCTAGCTCGGAGCC
GCCGTTAC-30(-224/10), 50-GCTAGCCAGAGCCTCCGA
AGACCGG-30( 205/10), 50-GCTAGCTCAGGCCCCGGCT
CAGG -30( 175/10), 50- GCTAGCCTGCCGCCCCTTTCCC
CTTTT-30(-65/10). The reverse primer was: 50-CCCCAAGCT
TGCCTACGGGGTGGCGCCAGCGAAC-30. Mutagenesis
of the Ets1 binding site was performed by PCR using
oligonucleotides carrying mutations at the presumed Ets1 core
recognition sites, in combination with the anti-sense primer
(þ10). These Mcl-1 promoter fragments were cloned into
promoter-less luciferase reporter plasmid pGL3-Basic Lucifer-
ase Vector (Promega, Madison, WI, USA). A 2.5kb fragment
of the Ets-1 promoter was subcloned into the pGL3-Basic
Luciferase Vector as described (Jorcyk et al., 1997; Wagner
et al., 2008). Cells were transiently transfected with luciferase
constructs together with the pRL-TK vector as a control for
transfection efﬁciency. The luciferase activity was measured
using the Dual Luciferase Reporter Assay System (Promega)
by Synergy 2 multi-detection microplate reader (BioTek,
Vinooski, VT, USA).
EMSA
Nuclear extracts were prepared using NE-PER Nuclear
Extraction Reagents Kit (Pierce, Rockford, IL, USA). The
DNA–protein binding was detected using the Light-Shift
chemiluminescent EMSA kit (Pierce). Binding reactions were
performed by adding 2mg of the nuclear extracts to a mixture
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Oncogenecontaining 40fmol of biotin-labeled, double-stranded probes
(50-CAGAGCCTCCGAAGACCGGAAGGCCCCGCT-30)i n
20ı`l of binding buffer. Antibodies were added to aliquots of
extracts for 30min before the addition of the reaction mixture.
Competition reaction mixtures contained a 100-fold
molar excess of non-labeled double-stranded oligo DNAs.
The mixtures were then resolved by polyacrylamide gel
electrophoresis and probe binding visualized by streptavidin
conjugated with horseradish peroxidase.
ChIP analysis
Analyses were performed using the ChIP Assay Kit (Upstate,
Lake Placid, NY, USA). Brieﬂy, cells were cross-linked using
1% formaldehyde at 371C for 10min. After washing, cells
were resuspended in 200ml SDS lysis buffer. DNA was sheared
to small fragments of 200 to 1000bp by sonication. The
recovered supernatant was incubated with antibodies over-
night at 41C with rotation. After washing, the precipitated
protein–DNA complexes were dissolved in 1 TE buffer and
incubated at 651C for 4h. DNA was then puriﬁed with
phenol/chloroform, and a fraction was used as PCR template
to detect the presence of the promoter sequences between  205
and þ10 of Mcl-1 using Mcl-1-speciﬁc primers: 50-CAGAGC
CTCCGAAGACCGG-30 (forward); 50-CCTACGGGGTGG
CGCCAGCGAAC-30(reverse).
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